Prot #ACP-103-034: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia

Project: Research project

Project Details

StatusFinished
Effective start/end date3/3/17 → 3/3/21

Funding

  • Quintiles, Inc. ((OE) Prot #ACP-103-034 // (OE) Prot #ACP-103-034)
  • ACADIA Pharmaceuticals Inc. ((OE) Prot #ACP-103-034 // (OE) Prot #ACP-103-034)